SCHEMBL30765748

SCHEMBL30765748

C[C@@H](Nc1ncc(N2CCOCC2)n(CC(=O)O)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 5/20 0.40
EGFR P00533 2/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
LIPG Q9Y5X9 1/20 0.37
MMP12 P39900 1/20 0.37
SYK P43405 2/20 0.37
PRKDC P78527 1/20 0.36
AURKA O14965 1/20 0.35
RPS6KB1 P23443 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766072 0.90 SOS1 (0.39) SOS1EGFRKDM4EALDH1A1GLA
SCHEMBL30766079 0.87 TSHR (0.38) SOS1EGFRALDH1A1GAALIPG
SCHEMBL30765728 0.82 MAPK1 (0.38) SOS1EGFRLIPGMAPK1
SCHEMBL30765730 0.81 SOS1 (0.41) SOS1EGFRAURKARPS6KB1LMNA
SCHEMBL31558425 0.80 MEN1 (0.36) EGFRMMP12AURKARPS6KB1MEN1
SCHEMBL31558541 0.78 SOS1 (0.39) SOS1EGFRKDM4EALDH1A1SYK
SCHEMBL30765863 0.78 GAA (0.38) KDM4EALDH1A1GAAMMP12LMNA
SCHEMBL30765626 0.78 USP2 (0.33) ALDH1A1GAAPRKDCLMNAHTT
Potassium Ion SCHEMBL30765480 0.78 F7 (0.36) EGFRMMP12LMNA
SCHEMBL30766075 0.77 HDAC6 (0.42) SOS1KDM4EALDH1A1GAAMMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed